IL-1β Enhances the Antiviral Effect of IFN-α on HCV Replication by Negatively Modulating ERK2 Activation.

Mingzhe Guo,Liqing Ye,Tao Yu,Lin Han,Qingchao Li,Peilan Lou,Tianyu Gan,Xia Jin,Hui Xiao,Guangxun Meng,Jin Zhong,Yongfen Xu
DOI: https://doi.org/10.1021/acsinfecdis.9b00506
IF: 5.578
2020-01-01
ACS Infectious Diseases
Abstract:Chronic hepatitis C infection is a leading cause of liver cirrhosis, which is linked to chronic hepatic inflammation. While there are multiple studies detailing with the proinflammatory role of interleukin-1β (IL-1β) in HCV-induced inflammasome signaling, the antiviral capacity of this cytokine has not been adequately investigated in the context of HCV infection or other members of Flaviridae. Our data indicated that IL-1β alone does not inhibit HCV replication, yet when in combination with IFN-ɑ, it can boost anti-HCV activity of IFN-ɑ, which is mediated by augmented STAT1 tyrosine 701 phosphorylation. Through signaling inhibitor screening, we found that ERK2 kinase is directly linked to enhanced activation of STAT1 complex. Our study found that IL-1β negatively affects ERK2 phosphorylation, which suggests that IL-1β mediated STAT1 tyrosine 701 phosphorylation employed kinase machinery of ERK2 other than JNK or P38 kinase. Our results identify IL-1β as a proinflammatory cytokine possessing wide spectrum synergistic antiviral capability via enhancing IFN-ɑ induced interferon-stimulated genes (ISGs) expression. More nuanced understanding of antiviral mechanisms of this important cytokine could facilitate development of new therapeutic options.
What problem does this paper attempt to address?